ATE493396T1 - Neue indazolcarboxamide und ihre verwendung - Google Patents

Neue indazolcarboxamide und ihre verwendung

Info

Publication number
ATE493396T1
ATE493396T1 AT05769167T AT05769167T ATE493396T1 AT E493396 T1 ATE493396 T1 AT E493396T1 AT 05769167 T AT05769167 T AT 05769167T AT 05769167 T AT05769167 T AT 05769167T AT E493396 T1 ATE493396 T1 AT E493396T1
Authority
AT
Austria
Prior art keywords
indazolcarboxamides
new
new indazolcarboxamides
Prior art date
Application number
AT05769167T
Other languages
English (en)
Inventor
Jeffrey Kerns
Christine Edwards
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE493396T1 publication Critical patent/ATE493396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
AT05769167T 2004-06-24 2005-06-24 Neue indazolcarboxamide und ihre verwendung ATE493396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58265504P 2004-06-24 2004-06-24
PCT/US2005/022870 WO2006002434A2 (en) 2004-06-24 2005-06-24 Novel indazole carboxamides and their use

Publications (1)

Publication Number Publication Date
ATE493396T1 true ATE493396T1 (de) 2011-01-15

Family

ID=35782386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05769167T ATE493396T1 (de) 2004-06-24 2005-06-24 Neue indazolcarboxamide und ihre verwendung

Country Status (21)

Country Link
US (1) US8501780B2 (de)
EP (1) EP1758578B1 (de)
JP (1) JP5017105B2 (de)
KR (1) KR20070043940A (de)
CN (1) CN101005836A (de)
AR (1) AR050253A1 (de)
AT (1) ATE493396T1 (de)
AU (1) AU2005258332A1 (de)
BR (1) BRPI0512533A (de)
CA (1) CA2571712A1 (de)
DE (1) DE602005025632D1 (de)
ES (1) ES2358579T3 (de)
IL (1) IL179747A0 (de)
MA (1) MA28727B1 (de)
MX (1) MXPA06014481A (de)
NO (1) NO20070076L (de)
PE (1) PE20060373A1 (de)
RU (1) RU2007102576A (de)
TW (1) TW200616967A (de)
WO (1) WO2006002434A2 (de)
ZA (1) ZA200609759B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
MX2007016541A (es) * 2005-06-30 2008-03-07 Smithkline Beecham Corp Compuestos quimicos.
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
MX2008010193A (es) * 2006-02-10 2008-11-27 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
JP5019768B2 (ja) * 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
GB0804591D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010120854A1 (en) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
JP2015214492A (ja) * 2012-09-07 2015-12-03 大日本住友製薬株式会社 ３−（４−ピペリジル）−インダゾール誘導体
HRP20211006T1 (hr) 2016-09-23 2021-09-17 Novartis Ag Spojevi indazola za uporabu kod ozljeda tetiva i/ili ligamenata
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2020263967A1 (en) * 2019-06-27 2020-12-30 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3342632A1 (de) 1983-11-25 1985-06-05 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
US5256673A (en) * 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
EP0279263B1 (de) 1987-02-10 1993-08-04 Abbott Laboratories Indol, Benzofuran, Benzothiophen enthaltende, Lipoxygenase hemmende Verbindungen
JPH0262875A (ja) * 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
IL95584A (en) 1989-09-07 1995-03-15 Abbott Lab Indole-, benzoporene- and benzothiophene compounds including lipoxygenase-inhibiting compounds and pharmaceutical compounds containing them
US5254473A (en) * 1990-03-16 1993-10-19 Jp Laboratories Solid state device for monitoring integral values of time and temperature of storage of perishables
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
AU6215594A (en) 1993-03-18 1994-10-11 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
DE19500689A1 (de) 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
IL122427A0 (en) 1995-06-07 1998-06-15 Sugen Inc Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP1077213A3 (de) 1996-06-14 2001-06-13 Eli Lilly And Company Hemmung der Serotoninwiederaufnahme
JP2001506230A (ja) 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
KR20010022581A (ko) 1997-08-06 2001-03-26 피터 지. 스트링거 타키키닌 수용체 길항제인 2-아실아미노프로판아민
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
JP2002515891A (ja) 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
JP4342101B2 (ja) 1998-02-27 2009-10-14 キッセイ薬品工業株式会社 インドール誘導体および当該誘導体を含有する医薬品組成物
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
DE69912279T2 (de) 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
DE19928424A1 (de) 1999-06-23 2000-12-28 Aventis Pharma Gmbh Substituierte Benzimidazole
KR100718830B1 (ko) 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
BR0013122A (pt) * 1999-08-13 2002-04-30 Vela Pharmaceuticals Inc Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
CA2390531A1 (en) 1999-11-08 2001-05-17 Wyeth ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1209158A1 (de) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substitutierte beta-Carboline
EP1134221A1 (de) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituierte beta-Carboline als lkB-Kinasehemmer
AU2001255538B2 (en) * 2000-04-24 2006-03-30 Bristol-Myers Squibb Company Heterocycles that are inhibitors of IMPDH enzyme
RU2269523C2 (ru) 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
AU2001256714A1 (en) 2000-05-15 2001-11-26 Kissei Pharmaceutical Co. Ltd. Water-based liquid preparation
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
PT1309592E (pt) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc Pirazoles substituidos
AU2001279958A1 (en) 2000-08-17 2002-03-04 Celltech R And D Limited Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatorydisorders
US6868504B1 (en) * 2000-08-31 2005-03-15 Micron Technology, Inc. Interleaved delay line for phase locked and delay locked loops
CN1642973A (zh) * 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE319713T1 (de) 2000-10-03 2006-03-15 Bristol Myers Squibb Co Amino- substituierte tetracyclische verbindungen die als entzündungshemmende mittel nützlich sind, und diese enthaltende arzneimittel.
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
WO2002030423A1 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
AU2002211663A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
ATE392898T1 (de) 2000-10-26 2008-05-15 Amgen Inc Antiphlogistische mittel
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
BR0116323A (pt) 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
PL364111A1 (en) 2001-02-01 2004-12-13 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
KR20030097897A (ko) 2001-05-24 2003-12-31 레오 파마 에이/에스 신규한 피리딜 시아노구아니딘 화합물
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
PL367305A1 (en) * 2001-06-07 2005-02-21 F.Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
US6638679B2 (en) 2001-07-12 2003-10-28 Kodak Polychrome Graphics, Llc Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20030127204A1 (en) 2001-09-06 2003-07-10 Varnell Daniel F. Amphoteric polymer resins that increase the rate of sizing development
MXPA04002683A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos bencenosulfamida pirazolil sustituidos para el tratamiento de la inflamacion.
JP2005507922A (ja) * 2001-09-19 2005-03-24 ファルマシア・コーポレイション 炎症の治療のための置換されたインダゾール化合物
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
WO2003024935A2 (en) 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
JP2005523276A (ja) 2002-02-14 2005-08-04 グラクソ　グループ　リミテッド Ｎ−［（１−ｎ−ブチル−４−ピペリジニル）メチル］−３，４−ジヒドロ−２ｈ−［１，３］オキサジノ［３，２−ａ］インドール−１０−カルボキシアミド（ｓｂ２０７２６６）またはその塩および乾燥造粒操作を含む方法
EP1490371B1 (de) 2002-04-03 2007-08-15 Bristol-Myers Squibb Company Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AR039280A1 (es) * 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
MXPA04010952A (es) 2002-05-09 2005-01-25 Pharmacia Corp Compuestos de pirazolilo sustituidos para el tratamiento de la inflamacion.
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
CN1656093A (zh) 2002-05-30 2005-08-17 神经研究公司 3－取代的奎宁环及其用途
WO2003104218A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
CA2483890C (en) 2002-06-06 2012-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP4619786B2 (ja) 2002-08-29 2011-01-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための３−（スルホンアミドエチル）−インドール誘導体
US6911445B2 (en) 2002-09-12 2005-06-28 Wyeth Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
JP2006509765A (ja) 2002-11-22 2006-03-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
MXPA05005794A (es) * 2002-12-02 2005-08-16 Hoffmann La Roche Derivados de indazol como antagonistas del factor de liberacion de corticotropina.
WO2004053087A2 (en) * 2002-12-06 2004-06-24 Smithkline Beecham Corporation Nf-κb inhibitors
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7329668B2 (en) 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP1651629A1 (de) 2003-07-31 2006-05-03 Boehringer Ingelheim Pharmaceuticals Inc. Substituierte benzothiophenverbindungen und deren verwendungen
WO2005035527A1 (en) 2003-10-14 2005-04-21 Pharmacia Corporation Substituted pyrazinone compounds for the treatment of inflammation
EP1692128A1 (de) * 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazolverbindungen und verfahren zu deren anwendung als proteinkinaseinhibitoren
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
WO2006106326A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
JP5833804B2 (ja) 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US7956082B2 (en) * 2005-07-22 2011-06-07 Shionogi & Co., Ltd Indole derivative having PGD2 receptor antagonist activity
EP1940296A2 (de) * 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemische verbindungen
WO2007102883A2 (en) * 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
WO2007076286A2 (en) * 2005-12-16 2007-07-05 Smithkline Beecham Corporation Chemical compounds
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
ATE493411T1 (de) * 2006-09-22 2011-01-15 Glaxo Group Ltd Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors

Also Published As

Publication number Publication date
MXPA06014481A (es) 2007-03-01
JP5017105B2 (ja) 2012-09-05
US20070281933A1 (en) 2007-12-06
KR20070043940A (ko) 2007-04-26
CN101005836A (zh) 2007-07-25
PE20060373A1 (es) 2006-04-29
WO2006002434A2 (en) 2006-01-05
JP2008504296A (ja) 2008-02-14
TW200616967A (en) 2006-06-01
ES2358579T3 (es) 2011-05-11
DE602005025632D1 (de) 2011-02-10
BRPI0512533A (pt) 2008-03-25
CA2571712A1 (en) 2006-01-05
RU2007102576A (ru) 2008-07-27
IL179747A0 (en) 2007-05-15
EP1758578A2 (de) 2007-03-07
AR050253A1 (es) 2006-10-11
MA28727B1 (fr) 2007-07-02
ZA200609759B (en) 2007-10-31
EP1758578B1 (de) 2010-12-29
US8501780B2 (en) 2013-08-06
EP1758578A4 (de) 2009-05-27
WO2006002434A3 (en) 2006-06-15
AU2005258332A1 (en) 2006-01-05
NO20070076L (no) 2007-02-26

Similar Documents

Publication Publication Date Title
EP1746902A4 (de) Multilektin-affiniätschromatografie und verwendung dafür
ATE454384T1 (de) Neue pyridazinverbindung und ihre verwendung
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE409700T1 (de) Cannabinoid rezeptor-liganden und ihre verwendung
ATE520681T1 (de) N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE440093T1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE432975T1 (de) Flüssigwaschmittel und ihre verwendung
ATE391718T1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE465628T1 (de) Neue vip3-toxine und ihre verwendung
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
DE602006016189D1 (de) Pigmentdispergatoren und ihre Verwendung
DE602005025632D1 (de) Neue indazolcarboxamide und ihre verwendung
DE60318733D1 (de) Substituierte benzoxazinones und ihre verwendung
ATE387440T1 (de) Neue 4-benzylidenpiperidinderivate
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602005023145D1 (de) Neue androgene
DE502005002170D1 (de) Amphiphile polymerzusammensetzungen und ihre verwendung
DE602006009296D1 (de) Oligopeptide und ihre verwendung
ATE531259T1 (de) 2-alkyl-cycloalk(en)yl-carboxamide und ihre verwendung als fungizide
DE112005001951B8 (de) Piezoelektrische Keramikzusammensetzung und ihre Verwendung
EP1812055A4 (de) Chlamydien-antigene und ihre verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties